Valuation: Actinium Pharmaceuticals, Inc.

Market Cap 33.01M 28.29M 26.47M 24.2M 45.66M 3.16B 46.15M 313M 122M 1.59B 124M 121M 5.25B P/E 2026 *
7.5x
P/E 2027 * -1.55x
Enterprise Value 33.01M 28.29M 26.47M 24.2M 45.66M 3.16B 46.15M 313M 122M 1.59B 124M 121M 5.25B EV / Sales 2026 *
2.83x
EV / Sales 2027 * -
Free-Float
97.66%
Yield 2026 *
-
Yield 2027 * -
15/08 Actinium Pharmaceuticals Expands Manufacturing Capacity for Actimab-A Program CI
15/08 Actinium Pharmaceuticals, Inc. Amends Its Investigational New Drug CI
08/08 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
03/06 Actinium Pharmaceuticals Presents New Data on Atnm-400 Demonstrating Potent Activity in Prostate Cancer Models Resistant to All Three Approved Androgen Receptor Inhibitors CI
01/06 Actinium Pharmaceuticals, Inc. Appoints Steffen Heeger as Chief Medical Officer CI
01/06 Actinium Pharmaceuticals Presents New Radiochemistry Data Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates CI
30/05 Actinium Pharmaceuticals - receives two Canadian patent allowances for Actimab-A and Iomab-Act programs RE
30/05 Actinium Pharmaceuticals Receives Patent Allowances for Actimab-A and Iomab-Act Programs in Canada CI
09/05 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
06/05 Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of Atnm-400 Across Lung and Prostate Cancer and Radioconjugate Optimization CI
23/04 Actinium Pharmaceuticals, Inc. Highlights Transcriptional Reprogramming As Key Mechanism Underpinning Mutation-Agnostic Activity Of Actimab-A In AML CI
23/04 Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models At the 2026 American Association of Cancer Research Annual Meeting CI
07/04 Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for Atnm-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in Aml CI
1 day-4.55%
Current month+25.46%
1 month+22.09%
3 months-11.02%
6 months-1.87%
Current year-22.79%
1 week 1.04
Extreme 1.04
1.15
1 month 0.74
Extreme 0.735101
1.15
Current year 0.74
Extreme 0.735101
1.53
1 year 0.74
Extreme 0.735101
1.81
3 years 0.74
Extreme 0.735101
10.24
5 years 0.74
Extreme 0.735101
15.12
10 years 0.74
Extreme 0.735101
64.5
Manager TitleAgeSince
Chief Executive Officer 62 09/06/2017
Chief Tech/Sci/R&D Officer - 01/06/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 01/01/2008
Chairman 62 01/10/2013
Director/Board Member 68 08/11/2013
Date Insider Type Main position Quantity % Market Cap.
18/8/25 Tax

Chief Executive Officer

120,900 0.3876%
31/3/25 Issuer sale

Chief Financial Officer

706,588 2.2650%
31/3/25 Issuer sale

Chief Executive Officer

2,385,976 7.6484%
Change 5-day change 1-year change 3-year change Capi.($)
-4.55%0.00%-39.66%-82.44% 33.01M
-4.31%-6.62%+65.79%+98.02% 69.06B
-4.19%+1.05%+52.79%+85.53% 63.06B
-3.22%+23.17%+1.75%-5.23% 28.34B
-1.42%-3.38%-5.99%+465.34% 27.07B
+4.73%+4.78%+52.94%+14.77% 25.45B
-1.81%+0.38%+34.52%-18.33% 19.69B
+5.36%+4.61%+270.18%+415.10% 19.19B
-0.86%-4.42%+10.37%+513.25% 15.95B
+0.87%+4.26%+41.21%+150.80% 13.52B
Average -0.94%+3.52%+48.39%+163.68% 28.14B
Weighted average by Cap. -1.80%+1.66%+55.78%+152.18%

Financials

2026 *2027 *
Net sales 11.67M 10M 9.35M 8.55M 16.14M 1.12B 16.31M 111M 43.04M 561M 43.8M 42.86M 1.86B -
Net income 4.91M 4.2M 3.93M 3.6M 6.79M 470M 6.86M 46.55M 18.1M 236M 18.42M 18.02M 781M -31.71M -27.17M -25.42M -23.24M -43.86M -3.04B -44.32M -301M -117M -1.52B -119M -116M -5.04B
Net Debt - -
Logo Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
Employees
27
Date Price Change Volume
24/08/26 USD 1.050 -4.55% 64,454
21/08/26 USD 1.100 -1.79% 144,008
20/08/26 USD 1.120 -0.88% 121,416
19/08/26 USD 1.130 +4.63% 183,406
18/08/26 USD 1.080 +2.86% 211,197
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.050USD
Average target price
3.500USD
Spread / Average Target
+233.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATNM Stock